 There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation ASCT. This study aimed to evaluate G-CSF efficiency and safety based on haemograms, transfusion needs and complications of two biosimilars Zarzio and Ratiograstim compared to those of Neupogen for our patients who underwent ASCT. 